PGE2/EP4 skeleton interoception activity reduces vertebral endplate porosity and spinal pain with low-dose celecoxib
Open Access
- 2 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Research
- Vol. 9 (1), 1-14
- https://doi.org/10.1038/s41413-021-00155-z
Abstract
Skeletal interoception regulates bone homeostasis through the prostaglandin E2 (PGE2) concentration in bone. Vertebral endplates undergo ossification and become highly porous during intervertebral disc degeneration and aging. We found that the PGE2 concentration was elevated in porous endplates to generate spinal pain. Importantly, treatment with a high-dose cyclooxygenase 2 inhibitor (celecoxib, 80 mg·kg−1 per day) decreased the prostaglandin E2 concentration and attenuated spinal pain in mice with lumbar spine instability. However, this treatment impaired bone formation in porous endplates, and spinal pain recurred after discontinuing the treatment. Interestingly, low-dose celecoxib (20 mg·kg−1 per day, which is equivalent to one-quarter of the clinical maximum dosage) induced a latent inhibition of spinal pain at 3 weeks post-treatment, which persisted even after discontinuing treatment. Furthermore, when the prostaglandin E2 concentration was maintained at the physiological level with low-dose celecoxib, endplate porosity was reduced significantly, which was associated with decreased sensory nerve innervation and spinal pain. These findings suggest that low-dose celecoxib may help to maintain skeletal interoception and decrease vertebral endplate porosity, thereby reducing sensory innervation and spinal pain in mice.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01 AR071432)
This publication has 60 references indexed in Scilit:
- Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trialsThe Lancet, 2013
- ISSLS Prize WinnerSpine, 2012
- Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysisBMJ, 2011
- The rat intervertebral disk degeneration pain model: relationships between biological and structural alterations and painArthritis Research & Therapy, 2011
- CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neuronsGenes & Development, 2010
- A Serotonin-Dependent Mechanism Explains the Leptin Regulation of Bone Mass, Appetite, and Energy ExpenditureCell, 2009
- Celecoxib, NSAIDs and the skeletonDrugs of Today, 2008
- CJ-023,423, a Novel, Potent and Selective Prostaglandin EP4Receptor Antagonist with Antihyperalgesic PropertiesThe Journal of pharmacology and experimental therapeutics, 2007
- Celecoxib for rheumatoid arthritisPublished by Wiley ,2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000